Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

Robert J. Motzer; Robert Amato; Mary Todd; Wen J.Poo Hwu; Roger Cohen; Jose Baselga; Hyman Muss; Michael Cooper; Richard Yu; Michelle S. Ginsberg; Michael Needle

doi:10.1023/A:1022928612511

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

Robert J. Motzer, Robert Amato, Mary Todd, Wen J.Poo Hwu, Roger Cohen, Jose Baselga, Hyman Muss, Michael Cooper, Richard Yu, Michelle S. Ginsberg, Michael Needle

Melanoma Medical Oncology

Research output: Contribution to journal › Article › peer-review

145 Scopus citations

Abstract

Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m² followed by weekly maintenance doses at 250 mg/m². None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.

Original language	English (US)
Pages (from-to)	99-101
Number of pages	3
Journal	Investigational New Drugs
Volume	21
Issue number	1
DOIs	https://doi.org/10.1023/A:1022928612511
State	Published - Feb 2003

Keywords

C225
Cetuximab
Monoclonal antibody
Renal cell carcinoma

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1022928612511

Cite this

@article{87bbfea4e8d24fbf9dd1146e7b43d560,

title = "Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma",

abstract = "Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.",

keywords = "C225, Cetuximab, Monoclonal antibody, Renal cell carcinoma",

author = "Motzer, {Robert J.} and Robert Amato and Mary Todd and Hwu, {Wen J.Poo} and Roger Cohen and Jose Baselga and Hyman Muss and Michael Cooper and Richard Yu and Ginsberg, {Michelle S.} and Michael Needle",

year = "2003",

month = feb,

doi = "10.1023/A:1022928612511",

language = "English (US)",

volume = "21",

pages = "99--101",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

AU - Motzer, Robert J.

AU - Amato, Robert

AU - Todd, Mary

AU - Hwu, Wen J.Poo

AU - Cohen, Roger

AU - Baselga, Jose

AU - Muss, Hyman

AU - Cooper, Michael

AU - Yu, Richard

AU - Ginsberg, Michelle S.

AU - Needle, Michael

PY - 2003/2

Y1 - 2003/2

N2 - Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.

AB - Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m2 followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.

KW - C225

KW - Cetuximab

KW - Monoclonal antibody

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=12444251187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12444251187&partnerID=8YFLogxK

U2 - 10.1023/A:1022928612511

DO - 10.1023/A:1022928612511

M3 - Article

C2 - 12795534

AN - SCOPUS:12444251187

SN - 0167-6997

VL - 21

SP - 99

EP - 101

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this